Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 28789


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28789

License Grant
The Licensor entered into a License Agreement with the Licensee in relation to EVO 022, EVO 033 and EVO 044. EVO 022 is a combination drug therapy which is focused on the treatment of breast cancer. EVO 033 is a reformulation of an off patent novel anti microtubule agent targeted against breast cancer. EVO 044 utilises a stem cell technology to form bone marrow.
License Property
The Licensor acquires, develops and commercializes drugs to treat a variety of cancers, including pancreatic, renal and small-cell lung cancer.
Field of Use
The Licensee is a Pharmaceutical Company.

IPSCIO Record ID: 4616

License Grant
The British Licensor and the Licensee entered into the License agreement in relation to EVO 011. The research Agreement is for a period of three years and provides for total expenditure of $1,438,659 over the course of the three years.
License Property
EVO 011 is a monoclonal antibody which targets most forms of cancer that is being developed by the Licensor for the Licensee.
EVO 011 is a monoclonal antibody that is a receptor blocker. EVO 011 stops cancer cell proliferation, and inhibits cancer cells from metasizing, blocking Angiogenesis II. It significantly reduces cancer invasion and will be used as an adjunct therapy. This drug may also have a use in cardiovascular disease.
Field of Use
The Licensee's lead compound is EVO 011, a monoclonal antibody which targets

most forms of cancer.

IPSCIO Record ID: 256873

License Grant
The Taiwanese Licensor hereby grants sole licensing rights to Licensee, a shareholder, in the Field and in the Territory under the Intellectual Property, Confidential Information, Data and Trademark, to develop Product.
License Property
Drug and therapeutic use of five products BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia
The new drug products that originate from Maitake Combination Therapy. The three drugs licensed from BriVision to Rgene are ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy.
Field of Use
Maitake Combination Therapy for indications including but not limited to the following breast cancer, brain tumor, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, nasopharyngeal carcinoma, prostate cancer, cervix cancer, oral/ pharynx/larynx cancer, lung cancer, leukemia, myeloma, lymphoma, gastric cancer, thyroid cancer, esophageal cancer, gastric cancer, small intestine cancer, large intestine/colon/rectal cancer, ovary cancer, skin cancer, head and neck, soft tissue sarcoma, bone tumor, bladder cancer, and cholangiocarcinomab.”

IPSCIO Record ID: 29382

License Grant
Ixabepilone was developed by the Company, but is subject to a License Agreement with a German Licensor, relating to epothilone technologies.
License Property
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog[1] developed as a cancer drug.  Ixempra(ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs.

The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.

Field of Use
In October 2007, the FDA approved ixabepilone in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated, and in monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

IPSCIO Record ID: 5086

License Grant
The Company entered into a license agreement with the Canadian University whereby it obtained an exclusive worldwide license (the CD77 License), with the right to grant sublicenses, to make, have made, use and sell any product using any method of selectively purging CD77 positive cells from bone marrow described in certain U.S. and PCT patent applications (U.S. Patent No. 5,801,145), and to use, have used, make and have made the method for treatment of Non-Hodgkin’s Lymphomas described in such applications (the Licensed CD77 Technology) for the purpose of producing products using the CD77 Technology (Licensed CD77 Products).
Field of Use
Although no assurance can be given, the Licensed CD77 Technology may lead to improved interventions for cancer patients whose therapies include autologous stem cell transplantation (ASCT).

Preliminary research indicates that stem cells may be removed from patients undergoing radiation or chemotherapy, and then transplanted back into the patient using the Licensed CD77 Technology.  Shiga-like toxin 1, a bacterial toxin, is used as an agent to selectively kill cancer cells in the patient’s bone marrow without harming the essential marrow cells which allow regeneration of marrow’s capacity for forming blood cells.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.